BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16925132)

  • 1. The cytokines and the B-cell malignancies: a new spin on maximizing therapeutic outcomes.
    Snively AH
    ONS News; 2006; 21(8 Suppl):13-4. PubMed ID: 16925132
    [No Abstract]   [Full Text] [Related]  

  • 2. NCCN: Non-Hodgkin's lymphoma.
    Zelenetz AD; Hoppe RT;
    Cancer Control; 2001; 8(6 Suppl 2):102-13. PubMed ID: 11760551
    [No Abstract]   [Full Text] [Related]  

  • 3. NCCN preliminary non-Hodgkin's lymphoma practice guidelines.
    Oncology (Williston Park); 1997 Nov; 11(11A):281-46. PubMed ID: 9430195
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hematology 2010].
    Dreyling M; Subklewe M; Braess J; Spiekermann K
    Dtsch Med Wochenschr; 2010 Jun; 135(25-26):1322-5. PubMed ID: 20556691
    [No Abstract]   [Full Text] [Related]  

  • 5. Non-Hodgkin's lymphomas: understanding monoclonal antibody therapy.
    Hendrix C
    ONS News; 2006; 21(8 Suppl):19-20. PubMed ID: 16925135
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary cutaneous B-cell lymphoma: subtypes, treatment and outcome of 10 cases.
    Onsun N; Su O; Kural YB; Erdemoglu Y; Buyukbabani N; Demirkesen C; Aydin Y
    Acta Derm Venereol; 2011 Jun; 91(4):476-8. PubMed ID: 21537819
    [No Abstract]   [Full Text] [Related]  

  • 7. The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma.
    Dunleavy K; Staudt LM; Wilson WH
    Leuk Lymphoma; 2007 Jun; 48(6):1061-3. PubMed ID: 17577765
    [No Abstract]   [Full Text] [Related]  

  • 8. The differential diagnosis between primary cutaneous large B-cell lymphoma and cutaneous follicular lymphoma: prognostic and therapeutic implications.
    Fernandez-Flores A; Smucler-Simonovich A; Escalante F; Manjon JA
    Am J Dermatopathol; 2011 Dec; 33(8):819-26. PubMed ID: 22042259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
    Koç ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF
    J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful autologous peripheral blood stem cell transplantation with rituximab administration for pediatric diffuse large B-cell lymphoma.
    Imamura T; Yoshihara T; Morimoto A; Ishida H; Sugimoto T; Imashuku S
    Pediatr Hematol Oncol; 2006; 23(1):19-24. PubMed ID: 16326408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Application of gene expression profiling in molecular classification, prognosis and therapy of B-cell lymphoma].
    Mao ZR; Zhou R; Zhang XX; Mueller-Hermelink Hk; Rosenwald A
    Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):785-9. PubMed ID: 20079025
    [No Abstract]   [Full Text] [Related]  

  • 13. Monoclonal antibodies in lymphoma: the first decade.
    Link BK; Friedberg JW
    Semin Hematol; 2008 Apr; 45(2):71-4. PubMed ID: 18381100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody therapies for follicular non-Hodgkin's lymphomas: moving toward a cure.
    McGee L
    ONS Connect; 2007; 22(8 Suppl):39-40. PubMed ID: 17824558
    [No Abstract]   [Full Text] [Related]  

  • 16. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
    Niitsu N; Hayama M; Okamoto M; Khori M; Higashihara M; Tamaru J; Hirano M
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4077-82. PubMed ID: 15217942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consolidation and maintenance rituximab therapy in chronic lymphocytic leukemia.
    Lamanna N; Weiss MA
    Curr Oncol Rep; 2008 Sep; 10(5):363-4. PubMed ID: 18706262
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoclonal antibody to treat lymphoma.
    Marwick C
    JAMA; 1997 Aug; 278(8):616, 618. PubMed ID: 9272879
    [No Abstract]   [Full Text] [Related]  

  • 20. Transformed follicular non-Hodgkin lymphoma.
    Casulo C; Burack WR; Friedberg JW
    Blood; 2015 Jan; 125(1):40-7. PubMed ID: 25499449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.